Athenex, which is developing oral chemotherapies and kinase inhibitors for cancer in the US and China, raised $66 million by offering 6 million shares at $11, the low end of the range of $11 to $13. Athenex plans to list on the Nasdaq under the symbol ATNX. Credit Suisse, Deutsche Bank and J.P. Morgan acted as lead managers on the deal.
